LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Stevanato Group SpA

Geschlossen

BrancheGesundheitswesen

16 3.09

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

15.8

Max

16.11

Schlüsselkennzahlen

By Trading Economics

Einkommen

10M

49M

Verkäufe

23M

303M

KGV

Branchendurchschnitt

26.833

121.746

EPS

0.162

Dividendenrendite

0.35

Gewinnspanne

16.205

Angestellte

5,521

EBITDA

10M

73M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+48.84% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.35%

2.26%

Nächstes Ergebnis

5. März 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.3B

4.4B

Vorheriger Eröffnungskurs

12.91

Vorheriger Schlusskurs

16

Nachrichtenstimmung

By Acuity

50%

50%

127 / 351 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Stevanato Group SpA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Feb. 2026, 23:21 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. Feb. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. Feb. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. Feb. 2026, 23:06 UTC

Ergebnisse

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Shareholders to Receive A$5.20/Share in Cash

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. Feb. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. Feb. 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. Feb. 2026, 20:48 UTC

Ergebnisse

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. Feb. 2026, 20:47 UTC

Ergebnisse

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. Feb. 2026, 20:46 UTC

Ergebnisse

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. Feb. 2026, 20:45 UTC

Ergebnisse

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. Feb. 2026, 20:43 UTC

Ergebnisse

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope Net Debt A$2.2 Million at Dec. 31

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. Feb. 2026, 20:41 UTC

Ergebnisse

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. Feb. 2026, 20:39 UTC

Ergebnisse

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Peer-Vergleich

Kursveränderung

Stevanato Group SpA Prognose

Kursziel

By TipRanks

48.84% Vorteil

12-Monats-Prognose

Durchschnitt 23.83 USD  48.84%

Hoch 30 USD

Tief 17.5 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Stevanato Group SpA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

2

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

21.56 / 22.61Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

127 / 351 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
help-icon Live chat